Midterm Elections’ Impact on Healthcare
Analysis
After many controversial reform proposals during AMLO’s administration, the sector sees a calmer future.
Karel Fucikovsky
Expert Contributor
Karel Fucikovsky
Director of Medical Care Mexico
Pierre Fabre Pharma
https://pierre-fabre.com
Tourism and its associated services are in intensive care. It’s time to include them in the national vaccination strategy, says Karel Fucikovsky
Pharmaceutical Industry at the Front Line of the Pandemic
Video
The pharmaceutical industry is going through intensive therapy, not as a patient but as an ally in supporting the health sector and its users
Rafael Gual, Arturo de la Rosa, Karel Fucikovsky, Juan Luis Serrano, Sanchez Devanny, Pierre Fabre Mexico, AbbVie, AbbVie Mexico, Canifarma
News Article
The pharmaceutical industry is going through intensive therapy, not as a patient but as an ally in supporting the health sector and its users
Medications
Weekly Roundups
Sandra Sanchéz-Oldenhage’s call for more customer-centricity as pharmaceutical companies have to adapt to new realities.
MHR2018_Book_Ch10_Karel-Fucikovsky
View from the Top
Karel Fucikovsky
Pharma Director
Pierre Fabre Mexico
Strengthening its focus on oncology, Pierre Fabre is looking to make Mexico a primary destination for its solutions.
Karel Fucikovsky
View from the Top
Karel Fucikovsky
Director General
Pierre Fabre Médicament
Pierre Fabre is the third-largest French pharmaceutical laboratory.
Karel Fucikovsky
Roundtable
Karel Fucikovsky
Director General
Pierre Fabre Médicament LATAM

Overall, market access poses challenges and question marks for all players. We are a heavily regulated industry and even more so due to our internal compliance with government policies. In Mexico and Latin America, our time to market for drugs is getting slower and our capability as a transnational company versus local players at times cannot be compared. Registration for market authorization for new products is one of the hardest hurdles to comply with for many companies, especially for innovative drugs and therapies, even considering that the authorities have simplified processes and time frames. Unfortunately, we have examples of novel drugs that have been in the registration process for almost six years and there is still no answer as to when market authorization will be granted. This obviously generates financial and business forecasting issues for us, plus big questions from our partners in Europe trying to understand the situation.

Companies have faced last year, such as fluctuating exchange rates and insecurity.
Karel Fucikovsky
View from the Top
Karel Fucikovsky
Director General
Pierre Fabre Médicament
ierre Fabre is the third largest French pharmaceutical laboratory.
Subscribe to Pierre Fabre